Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of
single-dose MYOBLOC over a 1-year duration in adult subjects with lower limb spasticity,
followed by an open-label extension safety study of multiple doses.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Supernus Pharmaceuticals, Inc. US WorldMeds LLC
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A rimabotulinumtoxinB